deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT04492722

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Sponsor: AstraZeneca

Updated 25 times since 2020 Last updated: Nov 27, 2024 Started: Oct 1, 2020 Primary completion: Sep 6, 2022 Completion: Sep 6, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety concerns related to the study.

This PHASE2 trial investigates Chronic Kidney Disease and is currently terminated or withdrawn. AstraZeneca leads this study, which shows 25 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2024 · 14 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

25 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Jan 2025 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Jan 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Jan 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: CompletedTerminated

Show 20 earlier versions
  1. Nov 2022 — Jan 2024 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  2. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  3. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  4. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  5. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  6. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  7. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  8. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

  9. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  10. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  11. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  12. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  13. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  14. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  15. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  16. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  17. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  18. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  19. Sep 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE2

  20. Aug 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Emerald Clinical Inc.
  • Parexel
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .